SHANGHAI – Nanjing-based Legend Biotechnology Corp. has partnered with Janssen Biotech Inc., a subsidiary of Johnson & Johnson, to develop in CAR-B38M, a promising chimeric antigen receptor T cell (CAR T) therapy for multiple myeloma that targets B-cell maturation antigen (BCMA).